Overall Survival Data and Treatment Experience Improvements Reinforce the Impact of Rybrevant-based Regimens in EGFR-mutated Lung Cancer at WCLC 2026
September 12, 2026
September 12, 2026
RARITAN, New Jersey, Sept. 12 -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
New overall survival data and treatment experience improvements reinforce the impact of RYBREVANT(R) (amivantamab-vmjw)-based regimens in EGFR-mutated lung cancer at WCLC 2026
Presidential Symposium to feature final overall survival results for first-line RYBREVANT plus chemotherapy in EGFR exon 20 insertion-mutated NSCLC
Additional . . .
* * *
New overall survival data and treatment experience improvements reinforce the impact of RYBREVANT(R) (amivantamab-vmjw)-based regimens in EGFR-mutated lung cancer at WCLC 2026
Presidential Symposium to feature final overall survival results for first-line RYBREVANT plus chemotherapy in EGFR exon 20 insertion-mutated NSCLC
Additional . . .